Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients.
about
Anti-Cancer Stem-like Cell Compounds in Clinical Development - An Overview and Critical AppraisalSingle-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML.Dasatinib promotes Th1-type responses in granzyme B expressing T-cellsDasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia.Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV.Preclinical approaches in chronic myeloid leukemia: from cells to systemsImmunology and immunotherapy of chronic myeloid leukemia.Cancer stem cells in haematological malignancies.Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib.Therapeutic potential of cancer stem cells.Dynamical models of mutated chronic myelogenous leukemia cells for a post-imatinib treatment scenario: Response to dasatinib or nilotinib therapy.Single-cell proteomics: potential implications for cancer diagnostics.Approaches for targeting cancer stem cells drug resistance.Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cellsLeukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuationMonitoring of leukemia stem cells in chronic myeloid leukemia patients.Treating the chronic-phase chronic myeloid leukemia patient: which TKI, when to switch and when to stop?Pretreatment evaluation of fluorescence resonance energy transfer-based drug sensitivity test for patients with chronic myelogenous leukemia treated with dasatinib.CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting.Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia.IL1RAP expression as a measure of leukemic stem cell burden at diagnosis of chronic myeloid leukemia predicts therapy outcome.Another piece of the puzzle--optimal TKI selection before treatment discontinuation in CML.Cell sorting enables interphase fluorescence in situ hybridization detection of low BCR-ABL1 producing stem cells in chronic myeloid leukaemia patients beyond deep molecular remission.Evaluation of the primitive fraction by functional in vitro assays at the RNA and DNA level represents a novel tool for complementing molecular monitoring in chronic myeloid leukemia.
P2860
Q26744536-6534443B-EAD6-4165-BA9A-A29FD4D6E628Q33834587-18E95C4F-82FA-484B-8650-BA6A16FE6E64Q33930605-4D849946-A73E-4DCD-9F02-6692A74F5B48Q35194464-22A71AD0-4D0B-49D4-BED4-8BB8E57F131CQ36263943-3FB344E4-780A-46ED-9030-0CB2D87C26D8Q37469835-956E87A1-B4BC-497F-A65B-2174782FE594Q37676954-AD025400-92B4-4CDB-855C-60A3A6FB3989Q38175864-3D5DFE69-7683-4628-915D-F28203DB91DAQ38359714-99C72336-023A-4A2C-B12A-1AD6A8E1A6F2Q38376612-3525CA8C-836B-42AC-8AA3-058954610C55Q38446739-6547216D-FEA9-49D3-AA56-CAD71FA75B9DQ38692847-E52539D9-799D-4390-8DFA-9865C89B90ACQ38741203-6092FCFA-B661-4005-A565-1797A90D94E0Q38971795-7A1471F1-84D8-4209-AF94-315FBF2D47E6Q41472526-1DDA913D-F317-423E-AA16-70962547F0F9Q41610510-7F8214E9-3426-42B9-9E83-DAED9C41E785Q50044527-8ED72F1E-9B62-4BF6-B1E2-AEE28D5F5A59Q50997822-87F0409C-4D0A-45FA-960B-8E4250CDA384Q52714574-425AA5BD-447C-47FA-8CB6-ED66E8B4D7ECQ52735344-A2402A19-0004-4D82-A826-B598ED612ED9Q53215863-66820B7E-4561-4507-B44B-219AB84302CFQ53470550-D1617DBE-42D6-4773-83AA-C7761995EB00Q53605206-6EE63A92-BD37-4A78-A4B0-38E475AF3A99Q54204813-91F73556-CFC1-4957-9012-696B3DEA447BQ54979166-EAD57227-B267-4C0E-AFEA-C3629401EC4D
P2860
Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Impact of malignant stem cell ...... nic myeloid leukemia patients.
@en
Impact of malignant stem cell ...... nic myeloid leukemia patients.
@nl
type
label
Impact of malignant stem cell ...... nic myeloid leukemia patients.
@en
Impact of malignant stem cell ...... nic myeloid leukemia patients.
@nl
prefLabel
Impact of malignant stem cell ...... nic myeloid leukemia patients.
@en
Impact of malignant stem cell ...... nic myeloid leukemia patients.
@nl
P2093
P2860
P50
P356
P1433
P1476
Impact of malignant stem cell ...... nic myeloid leukemia patients.
@en
P2093
B Markevärn
B Simonsson
D Josefsen
H Hjorth-Hansen
Nordic CML Study Group (NCMLSG)
P2860
P2888
P304
P356
10.1038/LEU.2013.19
P577
2013-01-18T00:00:00Z
P5875
P6179
1037478860